Androgen News and Research

RSS

Taking anticoagulants alongside prostate cancer drugs does not increase bleeding risk

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants, investigators found no evidence of an increase in patients' bleeding or clotting risks, despite previous lab results that raised alarms.

9 Mar 2026

Serial liquid biopsies reveal evolution in advanced prostate cancer

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that androgen receptor (AR) alterations consistently emerged and were linked to poorer outcomes across therapies.

26 Feb 2026

Combination therapy may help overcome barrier in early-stage prostate cancer treatment

A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment.

26 Feb 2026

Tiny organism offers insight into neurological side effects of chemotherapy

Chemotherapy remains one of the most powerful tools in the fight against cancer, yet it often comes with significant long-term side effects that can dramatically affect patients' quality of life.

11 Feb 2026

PSMA PET/CT scans may predict prostate cancer recurrence, guide treatment

New research in the February 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to predict progression-free survival (PFS) and guide treatment planning in patients with rising prostate-specific antigen (PSA) levels following removal of the prostate.

9 Feb 2026

Which hair loss supplements actually work?

Researchers compare the effectiveness and safety of multiple dietary supplements for hair loss.

4 Feb 2026

Oxybutynin shows promise in managing hot flashes for prostate cancer patients

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to treat overactive bladder symptoms, reduces hot flashes compared to the placebo in men receiving hormone therapy for prostate cancer.

2 Feb 2026

New trial tests strategies to protect heart health during prostate cancer therapy

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by U.S. News & World Report, has opened a phase 2 clinical trial comparing three different strategies for protecting heart health in prostate cancer patients who receive androgen deprivation therapy (ADT), a potentially lifesaving hormone therapy.

26 Jan 2026

Metabolic reprogramming drives prostate cancer progression and treatment resistance

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy (ADT), the disease often progresses to castration-resistant prostate cancer (CRPC).

24 Jan 2026

Estrogen drives gut pain and explains higher rates of IBS in women

Women are dramatically more likely than men to suffer from irritable bowel syndrome (IBS), a chronic condition causing abdominal pain, bloating, and digestive discomfort.

18 Dec 2025

How Traditional Chinese Medicine may reshape the gut microbiome to ease insulin resistance in PCOS

This review synthesizes evidence that gut microbiota dysbiosis contributes to insulin resistance and symptom severity in polycystic ovary syndrome through impaired barrier function, inflammation, and altered microbial metabolites. It evaluates how Traditional Chinese Medicine may modulate these pathways while highlighting major gaps in clinical validation, safety, and standardization.

16 Dec 2025

Shorter hormone therapy may be enough for many men with prostate cancer

A study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that most of the benefits of androgen deprivation therapy (ADT) for prostate cancer occur within the first 9 to 12 months.

25 Nov 2025

Study shows how ketogenic eating improves hormonal balance in PCOS

The very low-carbohydrate ketogenic diet leads to meaningful reductions in weight, visceral adiposity, insulin resistance, and androgen excess in women with PCOS based on pooled randomized trials. Benefits appear consistent across studies, though high heterogeneity, short durations, and limited safety data highlight the need for longer-term comparative research.

19 Nov 2025